BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Abbott India Ltd.’s Q2 FY21 results were a mixed bag.
While margins, profitability were better than our estimates, revenues were lower due to slowdown in some therapeutic areas due to extended lockdown and lower footfalls at clinics.
Revenues remained muted at Rs 1054 crore. Ebitda margins expanded 344 basis points YoY to 22.8%, mainly due to 253 basis points improvement in gross margins to 45.5% and lower other expenditure.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Also Read: Abbott India Has Beaten Three Bear Markets
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR